The global gene therapy market is expected to grow from $5.77 billion in 2021 to $7.37 billion in 2022 at a compound annual growth rate (CAGR) of 27.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, causing inflation across goods and services effecting many markets across the globe. The gene therapy market is expected to reach $21.25 billion in 206 at a CAGR of 30.3%.
The gene therapy market includes revenues earned by entities by replacing a disease-causing gene with a healthy copy of the gene and inactivating a disease-causing gene that is not functioning properly. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
Gene therapy refer to a method for treating or curing sickness that alters a person's DNA. Gene treatments can function in a variety of ways: putting a healthy copy of the gene in place of a disease-causing gene, and putting a defective gene that causes an illness intoactive.
The main types of gene therapy are antigen, cytokine, suicide gene, and others. The antigen is a poison or other foreign substance that triggers an immunological response in the body, including antibody formation. The different vectors include viral vector, non-viral vector, and others and are used in oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, infectious diseases, and others. it is implemented in various sectors such as hospitals, homecare, specialty clinics, and others.
Incidences of cancer and other target diseases have been increasing significantly, which is calling for effective treatments, driving the growth of the gene therapy market. The rise in the number of cancer cases across the globe is likely to contribute to the growth of the gene therapy market during the forecast period.For instance, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, or roughly 1,670 fatalities every day. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43 percent of all new cancer cases.he four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all new cancer cases.Therefore, the rise in the cancer incidence rate globally is anticipated to boost the demand for the gene therapy market over the forthcoming years. Gene therapy is one of the most effective treatments in oncology. In this treatment, new genes are introduced into a cancerous cell or the surrounding tissue to cause cell death or slow the growth of cancer.
The high prices of gene therapy medicines are expected to limit the growth of the gene therapy market. The pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, the lack of cost-effective therapies for cancer and other diseases has influenced the health conditions of the population and has led to a low average life expectancy. Luxturna, a one-time treatment for acquired retinal eye disease, costs $850,000 in the US and £613,410 in the UK, despite a markdown that is applied through Britain's National Health Service. Zolgensma, for spinal muscular atrophy, is valued at $2.1 million in the US and Zynteglo, which focuses on a rare genetic blood disorder, costs $1.78 million, thus restraining the growth of the market.
The use of machine learning and artificial intelligence is gradually gaining popularity in the gene therapy market. Artificial intelligence (AI) is the simulation of human intelligence in machines, which are programmed to display their natural intelligence. Machine learning is a part of AI. Machine learning and AI help companies in the gene therapy market to conduct a detailed analysis of all relevant data, provide insights between tumor and immune cell interactions, and offer a more accurate evaluation of tissue samples often conflicted between different evaluators. For instance, since January 2020, GlaxoSmithKline, a pharmaceutical company, has been investing in AI to optimize gene therapy and develop off-the-shelf solutions for patients. It is also expected to reduce turnaround time and also the cost of gene therapies.
In December 2021, Novartis AG, a Switzerland-based pharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of medicines, acquired Gyroscope Therapeutics Holdings plc for an amount of $800 million. Through this acquisition, GT005, an experimental, one-time gene therapy now in Phase 2 for the treatment of persons with geographic atrophy (GA), will be added to the Novartis portfolio, increasing gene therapy research capabilities and bringing ophthalmic innovation to treat and prevent blindness globally. Gyroscope Therapeutics Holdings plc is a UK-based clinical stage biopharmaceutical company pioneering in the research and development of gene therapies for the treatment of eye related diseases.
The regions covered in the gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the gene therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
The market value is defined as the revenues that enterprises gain from goods and/or services solution within the specified market and geography through sales, grants, or donations in terms of currency (in USD ($) unless otherwise specified).
The revenues for a specified geography are consumption values - that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products.
The gene therapy market research report is one of a series of new reports that provides gene therapy market statistics, including gene therapy industry global market size, regional shares, competitors with a gene therapy market share, detailed gene therapy market segments, market trends and opportunities, and any further data you may need to thrive in the gene therapy industry. This gene therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
Major players in the gene therapy market are Novartis AG, Bluebird Bio Inc., Spark Therapeutics Inc., Audentes Therapeutics, Voyager Therapeutics, Applied Genetic Technologies Corporation, UniQure N.V., Celgene Corporation, Cellectis S.A. and Sangamo Therapeutics.
This product will be delivered within 1-3 business days.
The gene therapy market includes revenues earned by entities by replacing a disease-causing gene with a healthy copy of the gene and inactivating a disease-causing gene that is not functioning properly. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
Gene therapy refer to a method for treating or curing sickness that alters a person's DNA. Gene treatments can function in a variety of ways: putting a healthy copy of the gene in place of a disease-causing gene, and putting a defective gene that causes an illness intoactive.
The main types of gene therapy are antigen, cytokine, suicide gene, and others. The antigen is a poison or other foreign substance that triggers an immunological response in the body, including antibody formation. The different vectors include viral vector, non-viral vector, and others and are used in oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, infectious diseases, and others. it is implemented in various sectors such as hospitals, homecare, specialty clinics, and others.
Incidences of cancer and other target diseases have been increasing significantly, which is calling for effective treatments, driving the growth of the gene therapy market. The rise in the number of cancer cases across the globe is likely to contribute to the growth of the gene therapy market during the forecast period.For instance, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, or roughly 1,670 fatalities every day. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43 percent of all new cancer cases.he four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all new cancer cases.Therefore, the rise in the cancer incidence rate globally is anticipated to boost the demand for the gene therapy market over the forthcoming years. Gene therapy is one of the most effective treatments in oncology. In this treatment, new genes are introduced into a cancerous cell or the surrounding tissue to cause cell death or slow the growth of cancer.
The high prices of gene therapy medicines are expected to limit the growth of the gene therapy market. The pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, the lack of cost-effective therapies for cancer and other diseases has influenced the health conditions of the population and has led to a low average life expectancy. Luxturna, a one-time treatment for acquired retinal eye disease, costs $850,000 in the US and £613,410 in the UK, despite a markdown that is applied through Britain's National Health Service. Zolgensma, for spinal muscular atrophy, is valued at $2.1 million in the US and Zynteglo, which focuses on a rare genetic blood disorder, costs $1.78 million, thus restraining the growth of the market.
The use of machine learning and artificial intelligence is gradually gaining popularity in the gene therapy market. Artificial intelligence (AI) is the simulation of human intelligence in machines, which are programmed to display their natural intelligence. Machine learning is a part of AI. Machine learning and AI help companies in the gene therapy market to conduct a detailed analysis of all relevant data, provide insights between tumor and immune cell interactions, and offer a more accurate evaluation of tissue samples often conflicted between different evaluators. For instance, since January 2020, GlaxoSmithKline, a pharmaceutical company, has been investing in AI to optimize gene therapy and develop off-the-shelf solutions for patients. It is also expected to reduce turnaround time and also the cost of gene therapies.
In December 2021, Novartis AG, a Switzerland-based pharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of medicines, acquired Gyroscope Therapeutics Holdings plc for an amount of $800 million. Through this acquisition, GT005, an experimental, one-time gene therapy now in Phase 2 for the treatment of persons with geographic atrophy (GA), will be added to the Novartis portfolio, increasing gene therapy research capabilities and bringing ophthalmic innovation to treat and prevent blindness globally. Gyroscope Therapeutics Holdings plc is a UK-based clinical stage biopharmaceutical company pioneering in the research and development of gene therapies for the treatment of eye related diseases.
The regions covered in the gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the gene therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
The market value is defined as the revenues that enterprises gain from goods and/or services solution within the specified market and geography through sales, grants, or donations in terms of currency (in USD ($) unless otherwise specified).
The revenues for a specified geography are consumption values - that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products.
The gene therapy market research report is one of a series of new reports that provides gene therapy market statistics, including gene therapy industry global market size, regional shares, competitors with a gene therapy market share, detailed gene therapy market segments, market trends and opportunities, and any further data you may need to thrive in the gene therapy industry. This gene therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
Major players in the gene therapy market are Novartis AG, Bluebird Bio Inc., Spark Therapeutics Inc., Audentes Therapeutics, Voyager Therapeutics, Applied Genetic Technologies Corporation, UniQure N.V., Celgene Corporation, Cellectis S.A. and Sangamo Therapeutics.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary2. Gene Therapy Market Characteristics
3. Gene Therapy Market Trends And Strategies
4. Gene Therapy Market - Macro Economic Scenario
4.1 COVID-19 Impact On Gene Therapy Market
4.2 Ukraine-Russia War Impact On Gene Therapy Market
4.3 Impact Of High Inflation On Gene Therapy Market
5. Gene Therapy Market Size And Growth
5.1. Global Gene Therapy Historic Market, 2017-2022, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Gene Therapy Forecast Market, 2022-2027F, 2032F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market
6. Gene Therapy Market Segmentation
6.1. Global Gene Therapy Market, Segmentation By Gene Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
- Antigen
- Cytokine
- Suicide Gene
- Other Gene Types
- Viral Vector
- Non-Viral Vector
- Other Vectors
- Oncological Disorders
- Rare Diseases
- Cardiovascular Diseases
- Neurological Disorders
- Infectious Diseases
- Other Applications
- Hospitals
- Homecare
- Specialty Clinics
7.1. Global Gene Therapy Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
7.2. Global Gene Therapy Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
8. Asia-Pacific Gene Therapy Market
8.1. Asia-Pacific Gene Therapy Market Overview
- Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.3. Asia-Pacific Gene Therapy Market, Segmentation By Vector, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
9. China Gene Therapy Market
9.1. China Gene Therapy Market Overview
9.2. China Gene Therapy Market, Segmentation By Gene Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
9.3. China Gene Therapy Market, Segmentation By Vector, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
10. India Gene Therapy Market
10.1. India Gene Therapy Market, Segmentation By Gene Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
10.2. India Gene Therapy Market, Segmentation By Vector, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
11. Japan Gene Therapy Market
11.1. Japan Gene Therapy Market, Segmentation By Gene Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
11.2. Japan Gene Therapy Market, Segmentation By Vector, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
12. Australia Gene Therapy Market
12.1. Australia Gene Therapy Market, Segmentation By Gene Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
12.2. Australia Gene Therapy Market, Segmentation By Vector, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
13. Indonesia Gene Therapy Market
13.1. Indonesia Gene Therapy Market, Segmentation By Gene Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
13.2. Indonesia Gene Therapy Market, Segmentation By Vector, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
14. South Korea Gene Therapy Market
14.1. South Korea Gene Therapy Market, Segmentation By Gene Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
14.2. South Korea Gene Therapy Market, Segmentation By Vector, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
15. Western Europe Gene Therapy Market
15.1. Western Europe Gene Therapy Market Overview
15.2. Western Europe Gene Therapy Market, Segmentation By Gene Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
15.3. Western Europe Gene Therapy Market, Segmentation By Vector, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
16. UK Gene Therapy Market
16.1. UK Gene Therapy Market, Segmentation By Gene Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
16.2. UK Gene Therapy Market, Segmentation By Vector, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
17. Germany Gene Therapy Market
17.1. Germany Gene Therapy Market, Segmentation By Gene Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
17.2. Germany Gene Therapy Market, Segmentation By Vector, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
18. France Gene Therapy Market
18.1. France Gene Therapy Market, Segmentation By Gene Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
18.2. France Gene Therapy Market, Segmentation By Vector, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
19. Eastern Europe Gene Therapy Market
19.1. Eastern Europe Gene Therapy Market Overview
19.2. Eastern Europe Gene Therapy Market, Segmentation By Gene Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
19.3. Eastern Europe Gene Therapy Market, Segmentation By Vector, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
20. Russia Gene Therapy Market
20.1. Russia Gene Therapy Market, Segmentation By Gene Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
20.2. Russia Gene Therapy Market, Segmentation By Vector, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
21. North America Gene Therapy Market
21.1. North America Gene Therapy Market Overview
21.2. North America Gene Therapy Market, Segmentation By Gene Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
21.3. North America Gene Therapy Market, Segmentation By Vector, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
22. USA Gene Therapy Market
22.1. USA Gene Therapy Market Overview
22.2. USA Gene Therapy Market, Segmentation By Gene Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
22.3. USA Gene Therapy Market, Segmentation By Vector, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
23. South America Gene Therapy Market
23.1. South America Gene Therapy Market Overview
23.2. South America Gene Therapy Market, Segmentation By Gene Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
23.3. South America Gene Therapy Market, Segmentation By Vector, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
24. Brazil Gene Therapy Market
24.1. Brazil Gene Therapy Market, Segmentation By Gene Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
24.2. Brazil Gene Therapy Market, Segmentation By Vector, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
25. Middle East Gene Therapy Market
25.1. Middle East Gene Therapy Market Overview
25.2. Middle East Gene Therapy Market, Segmentation By Gene Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
25.3. Middle East Gene Therapy Market, Segmentation By Vector, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
26. Africa Gene Therapy Market
26.1. Africa Gene Therapy Market Overview
26.2. Africa Gene Therapy Market, Segmentation By Gene Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
26.3. Africa Gene Therapy Market, Segmentation By Vector, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
27. Gene Therapy Market Competitive Landscape And Company Profiles
27.1. Gene Therapy Market Competitive Landscape
27.2. Gene Therapy Market Company Profiles
27.2.1. Novartis AG
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. Bluebird Bio, Inc.
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. Spark Therapeutics, Inc.
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Audentes Therapeutics
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. Voyager Therapeutics
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance
28. Gene Therapy Pipeline Analysis
29. Key Mergers And Acquisitions In The Gene Therapy Market
30. Gene Therapy Market Future Outlook and Potential Analysis
31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Historic And Forecast Inflation Rates
31.4. Research Inquiries
31.5. About the Publisher
31.6. Copyright And Disclaimer
Executive Summary
Gene Therapy Global Market Report 2023 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on gene therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
Scope
Markets Covered
1) By Gene Type: Antigen; Cytokine; Suicide Gene; Other Gene types2) By Vector: Viral Vector; Non-Viral Vector; Other Vectors
3) By Application: Oncological Disorders; Rare Diseases; Cardiovascular Diseases; Neurological Disorders; Infectious Diseases; Other Applications
4) By End Users: Hospitals; Homecare; Specialty Clinics; Other End-Users
Companies Mentioned: Novartis AG; Bluebird Bio, Inc.; Spark Therapeutics, Inc.; Audentes Therapeutics; Voyager Therapeutics
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
A selection of companies mentioned in this report includes:
- Novartis AG
- Bluebird Bio, Inc.
- Spark Therapeutics, Inc.
- Audentes Therapeutics
- Voyager Therapeutics
- Applied Genetic Technologies Corporation
- UniQure N.V.
- Celgene Corporation
- Cellectis S.A.
- Sangamo Therapeutics
- Gilead Lifesciences, Inc.
- Orchard Therapeutics
- Sibiono GeneTech Co., Ltd.
- Gensight Biologics S.A.
- Shanghai Sunway Biotech Co., Ltd.
- Biogen
- Sarepta Therapeutics, Inc.
- Sangamo Therapeutics
- Audentes Therapeutics
- Regenxbio, Inc.
- Gegenxbio, Inc
- Oxford BioMedica plc.
- Dimension Therapeutics, Inc.
- Bristol-Myers Suibb Company
- Sanofi
- Taxus Cardium Pharmaceuticals Group, Inc. (Gene Biotherapeutics)
- Shrine Plc
- Benitech Biopharma
- Transgene
- Epeius Biotechnologies Corp.
- Calimmune, Inc.
Methodology
LOADING...